Quarterly UpdatesMay 7, 2026, 04:04 PM
Bluejay Diagnostics Advances Symphony IL-6 Clinical Study & Manufacturing
AI Summary
Bluejay Diagnostics provided a corporate update for Q1 2026, highlighting significant progress in its Symphony near-patient diagnostic platform. The company continued strong enrollment in its SYMON-II pivotal clinical study, reaching approximately 680 out of 750 target patients, and advanced manufacturing readiness for Symphony cartridges. Bluejay also maintained its objective for a future FDA 510(k) submission for its Symphony IL-6 test. Financially, the company reported $3.7 million in cash and cash equivalents and a net loss of $1.9 million for Q1 2026, consistent with the prior year.
Key Highlights
- SYMON-II pivotal clinical study enrolled approximately 680 of 750 target patients as of May 5, 2026.
- Resolved technical issues in Symphony cartridge manufacturing with Sanyoseiko Co. Ltd.
- Continued execution of FDA-focused regulatory strategy for Symphony IL-6, aiming for 510(k) submission.
- Cash and cash equivalents were approximately $3.7 million as of March 31, 2026.
- Reported a net loss of approximately $1.9 million for Q1 2026, consistent with Q1 2025.